Recent advances in chemotherapy for advanced gastric cancer

Table 1 Treatment results of cisplatin/5-fluorouracil for advanced gastric cancer in randomized trials

	Korea[8]	Japan[6]	EU[9]	US/EU[10]
No. of patients	105	103	134	112
Response rate (%)	34	51	20	23
Median progression-free survival (mo)	3.9	5.0	4.1	3.7
Median overall survival (mo)	7.3	8.5	7.2	8.5

EU: European Union; US: United States.

Table 2 Results of recent randomized trials with new cytotoxic agents

Study	Treatment	n	RR (%)	TTP (median, mo)	MST (mo)	P value
Van Cutsem et al (V325)[10]	CDDP + 5-FU	224	25	3.7	8.6	0.02
	D + CDDP + 5-FU	221	37	5.6	9.2
Dank et al (V306)[16]	CDDP + 5-FU	163	26	4.2	8.7	NS
	I + 5-FU/LV	170	32	5.0	9.0
Kang et al (ML17302)[17]	CDDP + 5-FU	137	29	5.0	9.3	NS
	CDDP + X	139	41	5.6	10.5
Cunningham et al (REAL-2)[18]	ECF	263	41	6.2	9.9	NS
	EOF	245	42	6.5	9.3
	ECX	250	46	6.7	9.9
	EOX	244	48	7.0	11.2
Boku et al (JCOG9912)[19]	5-FU	234	9	2.9	10.8	NS
	CDDP + I	236	38	4.8	12.3
	S-1	234	28	4.2	11.4
Koizumi et al (SPIRITS)[20]	S-1	150	31	4.0	11.0	NS
	CDDP + S-1	148	54	6.0	13.0

C: Cisplatin; D: Docetaxel; E: Epirubicin; F: 5-fluorouracil; I: Irinotecan; O: Oxaliplatin; X: Capecitabine; MST: Median survival time; TTP: Time to progression.

Table 3 Ongoing phase III clinical studies with monoclonal antibodies for gastric cancer

Study	Drug	Indication
ToGAa[39]	XP or FP ± trastuzumab	Advanced gastric cancer (HER2-positive)
AVAGAST	XP ± bevacizumab	Advanced gastric cancer
REAL-3	EOX ± panitumumab	Advanced esophagogastric cancer
EXPAND	XP ± cetuximab	Advanced esophagogastric cancer
MAGIC-2	Perioperative ECX ± bevacizumab	Operable gastric cancer

^aCompleted trial.